Indian competition regulator clears Novartis-GSK transactions

 
• By Anju Ghangurde

The Competition Commission of India (CCI) has cleared Novartis and GlaxoSmithKline's multi-segment transactions in India and ruled out any input/customer ''foreclosure'' concerns as a result of the firms' combination in the area of vaccines.

More from Anti-infective

More from Therapy Areas